Gilead, 'closely attuned to' potential US policy shifts, stands by long-acting PrEP launch

As potential HIV policy changes, looming tariffs and sweeping cuts across federal drug and health agencies are posing a concern for investors, Gilead is engaging with policymakers to stress the importance of lenacapivir for PrEP, CEO Daniel O'Day said.

Apr 25, 2025 - 16:48
 0
Gilead, 'closely attuned to' potential US policy shifts, stands by long-acting PrEP launch
As potential HIV policy changes, looming tariffs and sweeping cuts across federal drug and health agencies are posing a concern for investors, Gilead is engaging with policymakers to stress the importance of lenacapivir for PrEP, CEO Daniel O'Day said.